Given that our study captures the early onset of NAFLD, we measured the expression of IL-1β and the plasma biomarker, collagen IV (Col4), to assess the effects of AT1 blockade on liver health. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.